Updates from the ADA Annual Meeting. The LEADER and DEVOTE Trials
|
|
- Joanna Richardson
- 6 years ago
- Views:
Transcription
1 18/09/ Updates from the ADA Annual Meeting The LEADER and DEVOTE Trials Richard Pratley, M.D. Samuel Crockett Chair in Diabetes Research Director, Florida Hospital Diabetes Institute Senior Scientist and Diabetes Program Head, Translational Research Institute for Metabolism and Diabetes Adjunct Professor, Sanford Burnham Medical Disovery Institute Orlando, Florida Disclosures Grant support received by Florida Hospital from: Lexicon Pharmaceuticals Ligand Pharmaceuticals, Inc. Lilly Merck Sanofi-Aventis US LLC Takeda Speaker fees received by Florida Hospital from: AstraZeneca Novo Nordisk Takeda Consultancy fees received by Florida Hospital from: Boehringer-Ingelheim GlaxoSmithKline Hanmi Pharmaceutical Co. Ltd AstraZeneca Janssen Scientific Affairs LLC Ligand Pharmaceuticals, Inc. Lilly Merck Pfizer Eisai, Inc. Takeda All honoraria directed toward a non-profit which supports education and research DEVOTE: trial design 7637 patients randomised Insulin degludec once daily (blinded vial) + Standard of care IGlar U100 once daily (blinded vial) + Standard of care Follow-up period Follow-up period Randomisation Interim analysis (150 MACE accrued) End of treatment (633 MACE accrued) 30 days Inclusion criteria: Type 2 diabetes Current treatment with 1 oral or injectable antidiabetic agent(s) HbA 1c 7.0% OR HbA 1c <7.0% and basal insulin treatment 20 U/day High CV risk profile: CV or chronic kidney disease and aged 50 OR risk factors for CV disease and aged 60 Trial characteristics Primary endpoint Secondary endpoints Randomised, double blinded, active controlled, treat-to-target, event driven Time from randomisation to first occurrence of a 3-point MACE: cardiovascular death*, non-fatal myocardial infarction* or non-fatal stroke* Rate of severe hypoglycaemic episodes* Incidence of severe hypoglycaemic episodes* *Confirmed by the EAC; cardiovascular death includes undetermined cause of death; severe defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or take other corrective actions. BG concentrations may not be available during an event, but neurological recovery following the return of BG to normal is considered sufficient evidence that the event was induced by a low BG concentration BG, blood glucose; CV, cardiovascular; EAC, Event Adjudication Committee; MACE, major adverse cardiovascular event; U, unit Presented at ADA Annual Scientific Meeting, 2017
2 Patients with an event (%) 18/09/ Study drugs Type of insulin Insulin degludec New generation long-acting basal insulin analogue IGlar U100 First generation basal insulin analogue Mode of protraction Forms soluble multihexamers Precipitates as microcrystals Half life ~25 hours ~12 hours Day-to-day variability (AUC GIR,0 24h) Coefficient of variation 20% Coefficient of variation 80% AUC GIR, area under the curve for glucose infusion rate; IGlar U100, insulin glargine U100 Insulin glargine image data on file; Jonassen et al. Pharm Res. 2012;29: ; Heise et al. Expert Opin Drug Metab Toxicol 2015;11: ; Heise et al. Diabetes Obes Metab 2012;14: Baseline characteristics Parameter Insulin degludec IGlar U100 Total number of patients, n Age, years* Sex, Male, % Duration of diabetes, years* CV risk profile Established CV or CKD and age 50 years, % With CV risk factors and age 60 years, % BMI, kg/m 2 * HbA 1c, %* FPG, mmol/l* [mg/dl]* 9.4 [169.8] 9.6 [173.5] *Mean value. HbA 1c and FPG measured at randomisation. All other parameters measured at the screening visit BMI, body mass index; CKD, chronic kidney disease; FPG, fasting plasma glucose Presented at ADA Annual Scientific Meeting, 2017 Time to first 3-point MACE HR: 0.91 [0.78; 1.06] 95% CI Non-inferiority confirmed p< Time to first EAC-confirmed event (months) Insulin degludec (N) IGlar U100 (N) IGlar U100 Insulin degludec 356 patients 325 patients Full analysis set; Cox regression analysis accounting for treatment. Analysis includes events between randomization date and follow-up date. Patients without an event are censored at the time of last contact (phone or visit) CI, confidence interval; N, number of patients at risk; PYO, patient-years of observation Presented at ADA Annual Scientific Meeting, 2017
3 Mean number of events/100 PYO HbA 1c (%) % 18/09/ point MACE, 4-point MACE and allcause death Hazard ratio [95% CI] 3-point MACE 0.91 [0.78; 1.06] CV death* 0.96 [0.76; 1.21] Non-fatal myocardial infarction 0.85 [0.68; 1.06] Non-fatal stroke 0.90 [0.65; 1.23] point MACE Hazard ratio [95% CI] 0.92 [0.80; Favours insulin degludec Favours IGlar U ] Unstable angina requiring hospitalisation 0.95 [0.68; 1.31] All-cause death 0.91 [0.76; 1.11] Insulin IGlar U100 degludec N % N % *CV death includes undetermined cause of death; 4-point MACE defined as cardiovascular death*, non-fatal myocardial infarction, non-fatal stroke or unstable angina requiring hospitalisation Presented at ADA Annual Scientific Meeting, 2017 Similar mean HbA 1c 9.0 Insulin 8.5 degludec IGlar U % % ET Months since randomisation Insulin degludec (N) IGlar U100 (N) HbA 1c (mmol/mol) Observed mean change from baseline at month 24 Insulin degludec IGlar U Post hoc ETD: 0.01% [-0.05; 0.07] 95% CI Full analysis set ET, end treatment visit; ETD, estimated treatment difference Pratley R. Presented at ADA Annual Scientific Meeting, 2017 Rates of severe hypoglycaemia Rate ratio: 0.60 [0.48; 0.76] 95% CI p<0.001 IGlar U100 Insulin degludec Time from randomisation (months) Insulin degludec (N=3818) IGlar U100 (N=3819) E R E R EAC-confirmed episodes Full analysis set; Mean number of confirmed severe hypoglycaemic episodes. The number of events is analysed using a negative binomial regression model using a log link and the logarithm of the observation time (100 years) as offset E, number of events; R, events per 100 patient-years of observation Pratley R. Presented at ADA Annual Scientific Meeting, 2017
4 Mean number of events/100 PYO 18/09/ Rates of nocturnal severe hypoglycaemia IGlar U100 5 Insulin degludec Rate ratio: [0.31; 0.73] 95% CI p< Time from randomisation (months) Insulin degludec (N=3818) IGlar U100 (N=3819) N % E R N % E R EAC-confirmed episodes Full analysis set; Nocturnal hypoglycaemia: EAC-confirmed severe hypoglycaemic episode with an investigator-reported onset between 00:01 and 05:59. Mean number of nocturnal EAC-confirmed severe hypoglycaemic episodes. The number of events is analysed using a negative binomial regression model using a log link and the logarithm of the observation time (100 years) as offset Presented at ADA Annual Scientific Meeting, 2017 DEVOTE Trial summary DEVOTE confirms that insulin degludec does not increase the risk of adverse cardiovascular outcomes compared with IGlar U100 Glycaemic control (insulin degludec vs. IGlar U100): End of treatment mean HbA 1c values 7.55% vs. 7.50% Change in FPG levels -2.2 mmol/l vs mmol/l The rate of severe hypoglycaemia was significantly reduced with insulin degludec versus IGlar U100 in DEVOTE: 40% rate reduction of severe hypoglycaemia 53% rate reduction of nocturnal severe hypoglycaemia No safety issues were identified with insulin degludec compared with IGlar U100 LEADER: Study design Placebo run-in Liraglutide mg OD + standard of care Placebo + standard of care Safety follow-up Safety follow-up 2 weeks Screening Randomization (1:1) Double-blind Minimum duration 3.5 years Maximum 5 years Minimum 611 primary events End of treatment 30 days Key inclusion criteria T2DM, HbA1c 7.0% Antidiabetic drug naïve; OADs and/or basal/premix insulin Age 50 years and established CV disease or chronic renal failure or Age 60 years and risk factors for CV disease CV: cardiovascular; DPP-4i, dipeptidyl peptidase-4 inhibitor; GLP-1RA: glucagon-like peptide-1 receptor agonist; HbA 1c: glycated hemoglobin; OAD: oral antidiabetic drug; OD: once daily; T2DM: type 2 diabetes mellitus. Marso SP et al. N Engl J Med 2016;375:
5 18/09/ Baseline characteristics (mean ± SD unless stated) Liraglutide (N=4668) Placebo (N=4672) Male sex, N (%) 3011 (64.5) 2992 (64.0) Age, years 64.2 ± ± 7.2 Diabetes duration, years 12.8 ± ± 8.1 HbA 1c, % 8.7 ± ± 1.5 BMI, kg/m ± ± 6.3 Body weight, kg 91.9 ± ± 20.8 Systolic blood pressure, mmhg ± ± 17.7 Diastolic blood pressure, mmhg 77.2 ± ± 10.1 Heart failure*, N (%) 835 (17.9) 832 (17.8) *Heart failure includes New York Heart Association class I, II, and III. BMI: body mass index; HbA 1c: glycated haemoglobin; SD: standard deviation Marso SP et al. N Engl J Med 2016;375: Primary outcome CV death, non-fatal myocardial infarction, or non-fatal stroke The primary composite outcome in the time-to-event analysis was the first occurrence of death from cardiovascular causes, non-fatal myocardial infarction, or non-fatal stroke. The cumulative incidences were estimated with the use of the Kaplan Meier method, and the hazard ratios with the use of the Cox proportional-hazard regression model. The data analyses are truncated at 54 months, because less than 10% of the patients had an observation time beyond 54 months. CI: confidence interval; CV: cardiovascular; HR: hazard ratio. Marso SP et al. N Engl J Med 2016;375: LEADER: Individual components of the primary endpoint Number of patients Hazard ratio (95% CI) p-value Liraglutide Placebo N % R N % R Primary endpoint 0.87 (0.78 ; 0.97) CV death 0.78 (0.66 ; 0.93) Non-fatal MI 0.88 (0.75 ; 1.03) Non-fatal stroke 0.89 (0.72 ; 1.11) Hazard ratio (95% CI) Favours liraglutide Favours placebo Hazard ratios and p-values were estimated with the use of a Cox proportional-hazards model with treatment as a covariate %, percentage of group; CI, confidence interval; CV, cardiovascular; MI, myocardial infarction; N, number of patients; R, incidence rate per 100 patient years of observation Marso SP et al. N Engl J Med 2016;375:
6 HbA 1c (%) HbA 1c (mmol/mol) Proportion of patients (%) 18/09/ Antihyperglycemic medication at baseline Liraglutide Placebo Metformin Sulfonylureas Alphaglucosidase inhibitors TZDs Glinides Insulin Marso et al. N Engl J Med 2016;375: MACE by insulin use at baseline Hazard Ratio Liraglutide Placebo (95% CI) N % N % FAS MACE primary analysis 0.87 (0.78; 0.97) Post-hoc analysis MACE - Insulin use at baseline (Y/N) Yes 0.88 (0.75; 1.03) No 0.86 (0.74; 1.01) Favours Liraglutide Favours Placebo FAS: full analysis set; N: number of patients; % proportion of patients Pratley R. Presented at ADA Annual Scientific Meeting, 2017 LEADER: HbA 1c changes over time Placebo Liraglutide ETD at month 36: -0.40% 95% CI ( ) p< Time from randomization (months) Number of patients at each visit Liraglutide Placebo Data are estimated mean values from randomization to month 48. CI: confidence interval; ETD: estimated treatment difference; HbA 1c: glycated hemoglobin. Marso et al. N Engl J Med 2016;375:311 22
7 Mean number of episodes per 1000 subjects 18/09/ Severe hypoglycemia over time Placebo Liraglutide Rate ratio: % CI: (0.51; 0.93) p= Time since randomization (months) Liraglutide Placebo Number of subjects with severe hypoglycemia (%) 114 (2.4) 153 (3.4) Full analysis set. Mean number of severe hypoglycemic episodes. Number of events analyzed using a negative binomial regression model using a log link and the logarithm of the observation time (100 years) as offset. Treatment, sex, region and antidiabetic therapy at baseline included as fixed effects and age at baseline included as covariates CI: confidence interval Pratley R. Presented at ADA Annual Scientific Meeting, 2017 MACE by occurrence of severe hypoglycemia Hazard ratio (95% CI) Liraglutide N % Placebo N % First MACE Without severe hypoglycemia 0.88 (0.78 ; 0.98) With severe hypoglycemia 0.85 (0.52 ; 1.39) Hazard ratio (95% CI) Favors liraglutide Favors placebo Full analysis set. Post-hoc analysis. With hypoglycemia is subjects with one/more severe hypoglycemic episodes (irrespective of the timing between the severe hypoglycemia and the event of interest); without hypoglycemia is subjects without severe hypoglycemic episodes. The hazard ratios are estimated in Cox regression for each of the events of interest with an interaction between hypoglycemic episode (with, without) and treatment %: proportion of subjects with events; CI: confidence interval; MACE: major adverse cardiovascular event; N: number of subjects with events Pratley R. Presented at ADA Annual Scientific Meeting, 2017 LEADER Summary Liraglutide reduced the risk of major CV events in patients with T2DM at high CV risk Both risk of first event and recurrent events The reduction in CV events with liraglutide appeared independent of: Baseline insulin or CV medication use Initiation of insulin or SU/TZD during the trial Experiencing an episode of severe hypoglycemia It appears unlikely that the CV risk reduction with liraglutide can be fully explained by the observed differences in HbA 1c, body weight, SBP and lipids CV: cardiovascular; HbA 1c: glycated hemoglobin; SBP: systolic blood pressure; SU: sulfonylurea; T2DM: type 2 diabetes mellitus
8 9/18/2017 The CANVAS Trial (CANigloflozin cardiovascular Assessment Study) NEJM 2017; 377: Cres P Miranda MD FACC FACP FSCAI Interventional and Preventive Cardiology Assistant Clinical Professor of Medicine University of Nevada School of Medicine Las Vegas, Nevada Disclosures Dr. Miranda has received honoraria from: Amarin Amgen Astra-Zeneca Boehringer-Ingelheim Janssen Kowa Lilly Pfizer Regeneron Sanofi Baseline Characteristics NEJM 2017; 377:
9 9/18/2017 CV Risk Factor Changes NEJM 2017; 377: Cardiovascular Endpoints NEJM 2017; 377: Adverse Events NEJM 2017; 377:
10 9/18/2017 Subgroup Analysis NEJM 2017; 377: Cardiorenal Endpoints NEJM 2017; 377: Adverse Events NEJM 2017; 377:
11 9/18/2017 Why it's Important to Automate Insulin Delivery and a Focus on the MiniMed 670G Jennifer Sherr, MD, PhD Associate Professor, Pediatrics Monday, September 18 th, 2017 Presenter Disclosures Advisory Board Consultant: Bigfoot Biomedical Advisory Board Consultant: Insulet Corporation Advisory Board Consultant: Eli Lilly Consultant: Medtronic Diabetes 2 Objectives 1. Recognize the rationale for closed-loop insulin delivery for optimal care of persons with T1D 2. Define hybrid closed loop insulin delivery 3. Discuss the findings from the pivotal trial of the Minimed 670G system 4. Describe real-world use of the system 1
12 9/18/2017 Why do we need a CL system? 1. Present methods of diabetes treatments are largely unsuccessful in helping patients meet glycemic targets 2. Intensive management schemes are very burdensome and negatively impact quality of life for those living with diabetes, and their loved ones Current State of T1D n = 16,057 ADA Target Miller Diabetes Care 2015 What is Life with Diabetes? The Burdens of 6 2
13 9/18/2017 Anatomy of a Closed-Loop System 7 The spectrum of CL technologies Usual Care: Full OL SAP Insulin Suspension: Threshold Predictive Insulin Delivery: Overnight Hybrid CL The goal: Full CL Bihormonal CL Automation System Complexity Hybrid Closed Loop Therapy Usual Care: Full OL SAP Insulin Suspension: Threshold Predictive Insulin Delivery: Overnight Hybrid CL Automation System Complexity 3
14 Glucose (mg/dl) 9/18/2017 Hybrid CL: Benefits of Pre-meal Bolus setpoint meals Closed Loop (N=8) Hybrid CL (N=9) A Noon 6P MidN 6A Noon 6P Mean Daytime Peak Post Meals Full CL Hybrid Weinzimer, Diabetes Care Medtronic HCL System Guardian 3 Sensor MARD 9.64% 3-4 calibrations/day 10.55% 2 calibrations/day 11 Study Overview Study Design Multicenter: 9 sites in US & 1 site in Israel Single-arm (no control group) Non-randomized Study Protocol RUN-IN PERIOD: Pump + CGM 2 weeks Participants N=124 Type 1 2 years A1C < 10% Ages years Pump therapy 6 months, with or without CGM STUDY PERIOD: Auto Mode 3 months Day 1: HCL Training Day 7: Auto Mode turned ON 4
15 9/18/2017 Auto mode basics Basal insulin delivers every 5 minutes Algorithm and current SG determine 5-minute basal dose Targets SG of 120 mg/dl Temp target of 150 mg/dl may be used for up to 12 hours Correction bolus initiated when fingerstick BG > 150 mg/dl Algorithm determines sensitivity factor Uses fingerstick value and targets 150 mg/dl Considers active insulin Meal bolus initiated by patient entering carbs Carb ratio and number of carbs determine amount Baseline Characteristics Adolescents (n=30) Adults (n=94) Sex 16F / 14M 53F / 41M Age (years) 16.5 ± ± 12.8 Weight (kg) BMI (kg/m 2 ) Duration of diabetes (years) 67.4 ± ± ± ± ± ± 12.4 Total daily dose of insulin (units/kg/day) 0.8 ± ± 0.2 A1C at screening (%) 7.7 ± ± 0.9 Reduced Glycemic Variability Median and Interquartile Range of SG Values / Day & Night All Patients Adults Adolescents Run-in Phase Study Phase Hybrid closed loop resulted in: Increased time in range Reduced time spent low and high Reduced variability Less post-prandial excursion Bergenstal JAMA
16 Auto Basal Auto Basal Auto Basal Auto Basal 9/18/ G Pivotal Trial Run-In Adolescents Study Phase Run-In Adults Study Phase Average Sensor Glucose 163±19 159±12 146±22 148±14 Time in Target (71-180) 61±11 67±8 69±12 74±8 Time <70mg/dL 4.3± ± ± ±2.1 HbA1c 7.7± ± ± ±0.6 HCL Utilization n/a 76% n/a 88% 16 Garg DTT 2017 Decreased A1c and reduced hypos Line endpoint shows A1C in each cohort Red line shows mean A1C Bubble size proportional to percent of nocturnal SG values 50 mg/dl 4 Nights in a Single week on Automode Data on file 6
17 Auto Basal Auto Basal Auto Basal Auto Basal 9/18/2017 Daily insulin requirements are unique each day Data on file Insulin requirements also vary throughout the day MANUAL MODE AUTO MODE Target Range: mg/dl Auto basal Max Deiiver y Who is an ideal candidate? Willing to wear a pump and sensor Testing BG 3+ times/day (minimum of 2 BG/day) Willing to learn how to calibrate the sensor Giving most meal boluses Willing/able to give control over to a system Not a micromanager or type A. If they are, understand that they will need to develop trust and let go. Willing to participate in close follow-up with required frequent downloads Willing to give the system time to optimize 7
18 9/18/2017 Case Study using Commercial Product 14 year old girl Living with type 1 diabetes> 10 years On insulin pump therapy x 10 years Sometimes missed her meal boluses On Dexcom CGM prior to MiniMed 670G system start Plays sports all 3 seasons and in theater productions Week 1: manual mode Week 2: Automode 8
19 9/18/2017 Glycemia improves quickly MANUAL MODE AUTO MODE Average SG already improved by 20 % Estimated A1C significantly reduced (8.5% to 7.2%) Patient wearing Guardian Sensor 3 well & spending 93% of time in Auto Model Week 2: Automode Improvement in the time in Range 44% 73% PATIENT SPENDING 66% MORE TIME IN RANGE IN AUTO MODE MANUAL MODE AUTO MODE 9
20 9/18/2017 Real World Use of the System Pivotal Trial Data Time in target mg/dl Manual Mode Auto Mode 66.7% 72.2% Time in Auto Mode(%)* N/A 87.2% Sensor Wear* % Time Below 50 mg/dl 1.0% 0.6% Time Below 70 mg/dl 5.9% 3.3% Time Above 180 mg/dl 27.4% 24.5% Time Above 300 mg/dl 2.3% 1.7% A1C 7.4% 6.9% Mean SG ± SD 150 ± ± 14 12,389 patient days of data, 123 patients (three-month study) Time in target mg/dl Real World Data* Manual Mode Auto Mode 63.09% 75.58% Time in Auto Mode (%) N/A 92.9% Sensor Wear % Time Below 50 mg/dl 0.57% 0.31% Time Below 70 mg/dl 3.32% 2.23% Time Above 180mg/dL 33.59% 22.19% Time Above 300 mg/dl 2.86% 0.84% Est. A1C 7.22% 6.84% Mean SG ± SD 161 ± ± 47 >24, 000 patient days of data, 730 patients (on-going weekly surveillance) Bergenstal RM, et al. JAMA. 2016;316(13): *Data on file, unpublished from Medtronic Take Home Messages The vast majority of those living with T1D do not meet prescribed glycemic targets despite increased use of both pumps and sensors in clinical practice. Closed loop insulin delivery has been shown to increase time in target and improve control, especially in the overnight period. The first iterations of closed loop technology will be a hybrid approach, requiring the user to bolus for meals. The ability to integrate hybrid closed loop technology into our daily practice is here. We are in the midst of a technological revolution. 29 Thank you 30 10
21 8/24/2017 Renal Effects of Diabetes GEORGE L. BAKRIS, MD, F.A.S.N, F.A.S.H. PROFESSOR OF MEDICINE DIRECTOR, ASH COMPREHENSIVE HYPERTENSION CENTER THE UNIVERSITY OF CHICAGO MEDICINE CHICAGO, IL Key Facts about Diabetes Effect on the Kidney Most common cause of renal failure in the Western World About 30% of people with diabetes will develop renal failure and has a genetic predisposition To assess kidney function decline must perform check of serum creatinine annually along with spot albumin:creatinine ratio Presence of microalbuminuria is NOT indicative of diabetic nephropathy but rather inflammation. Levels > 300 mg/d equal nephropathy. Average rate of kidney function decline is <1 ml/min/yr. In diabetes it ranges from 3-8 ml/min/yr. Composite Ranking for Relative Risks by glomerular filtration rate (GFR) and Albuminuria (Kidney Disease: Improving Global Outcomes (KDIGO) Levey AS et.al. Kidney Int 2010; doi: /ki
22 Number of patients (millions) 8/24/2017 Projected Growth in CKD Stage 5 Prevalence million (60% diabetic) million 0.7 million Year Gilbertson D et al. Presented at the 2003 ASN annual meeting. Available from: Studies With Primary Renal Endpoints That Show Differences in Outcome: min=2.5 year F/U Diabetes Baseline GFR Captopril Trial, N Engl J Med, Hannadouche et.al B Med J, Bakris et.al Kidney Int., Bakris et.al Hypertension, IDNT, N Engl J Med, RENAAL, N Engl J Med, ALTITUDE, N Engl J Med, VA NEPHRON D, N Engl J Med, * Signifies GFR measured using iothalamate or iohexol Relationship Between Achieved BP and Decline in Kidney Function from Primary Renal Endpoint Trials Nondiabetes MDRD. N Engl J Med AIPRI. N Engl J Med REIN. Lancet AASK. JAMA Hou FF, et al. N Engl J Med Parsa A et.al. NEJM 2013 Diabetes Captopril Trial. NEJM Hannadouche T, et al. BMJ Bakris G, et al. Kidney Int Bakris G, et al. Hypertension IDNT. NEJM RENAAL. NEJM ALTITUDE NEJM Normal decline in GFR Update from Kalaitzidis R and Bakris GL In: Handbook of Chronic Kidney Disease Daugirdas J (Ed.)
23 mg/day 8/24/2017 New Concepts Microalbuminuria (MAU) is NOT synonymous with presence of kidney disease Treatment with an ACE inhibitor or ARB is not indicated in normotensive diabetics even if MAU is present. If >300 mg/day albuminuria ACEi or ARB must be part of BP lowering plan and goal BP should be <130/80 mmhg De Boer I et.al. Diabetes Care 2017; 40: Indicates continuous variable for CV/CKD risk Higher CV Risk and Presence of CKD and Vascular Dysfunction Inflammation; CV Risk and Vascular Dysfunction Normal Microalbuminuria (High Albuminuria) Molitch M and Bakris GL Diabetes Care 2014 Macroalbuminuria (Very High Albuminuria) Goal BP and Initial Therapy in Diabetic Kidney Disease or to Reduce CV /Renal Progression Risk? Goal BP Group Initial Therapy (mmhg) ADA (2017) <140/90 &<130/80-if tolerated ACE Inhibitor/ARB* KDIGO/KDOQI (NKF) (2012) <140/90 ACE Inhibitor/ARB 2014 Expert Panel <140/90 ACE Inhibitor/ARB* KDOQI (NKF) (2004) <130/80 ACE Inhibitor/ARB* JNC 7 (2003) <130/80 ACE Inhibitor/ARB* Am. Diabetes Assoc (2003) <130/80 ACE Inhibitor/ARB* Canadian HTN Soc. (2002) <130/80 ACE Inhibitor/ARB* Am. Diabetes Assoc (2002) <130/80 ACE Inhibitor/ARB* Natl. Kidney Foundation (2000) <130/80 ACE Inhibitor* British HTN Soc. (1999) <140/80 ACE Inhibitor WHO/ISH (1999) <130/85 ACE Inhibitor * Indicates JNC use VI with (1997) diuretic <130/85 ACE Inhibitor 9 3
24 8/24/2017 Renal Outcomes From Empa-Reg Wanner C et al. N Engl J Med DOI: /NEJMoa A egfr (according to CKD-EPI formula) over 192 weeks in all treated patients Rate of GFR decline in subgroup egfr < ml/min/year Recent analyses in those with egfr <60 ml/min/1.73m 2 showed Decline slowed to 1.83 ml/min/1.73m 2 Wanner C et al. N Engl J Med DOI: /NEJMoa Effects of canagliflozin on CV and renal outcome-cont. Neal B et.al. N Eng J Med
25 8/24/2017 Ongoing Phase 3 CV/Renal Outcome Trials and New Approved Agents to Help in Management TRIALS FIDELIO-DN(Finerenone-MRA inhibitor) SONAR-(Atratsantan-ETA1 receptor blocker) CREDENCE-( Canagliflozin-SGLT2 antagonist Summary CKD Progression has slowed from an average of 5-7 ml/min/year in the 1990 s to an average of 2-3 ml/min/year in 2015 clinical trials. Three ongoing trials with different agents added to standard of care will determine if the rate of decline in kidney function can be normalized. No data to support advantage on CKD outcome in elderly without proteinuria. 5
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI. Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona
PROTEZIONE DAL DANNO RENALE NEL DIABETE TIPO 2: RUOLO DEI NUOVI FARMACI Massimo Boemi UOC Malattie Metaboliche e Diabetologia IRCCS INRCA Ancona Disclosure Dr Massimo Boemi has been granted as speaker
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationT2 Diabetes in Sep-16. Stephen Leow Disclosures. Why do we treat diabetes? Agenda. Targets
Stephen Leow Disclosures I have received honoraria, sat on the advisory boards or received grants from Novo Nordisk, Sanofi Aventis, Eli Lilly, Boehringer Ingleheim, Jansenn Cilag, Mundipharma, BioCSL,
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationSafety profile of Liraglutide: Recent Updates. Mohammadreza Rostamzadeh,M.D.
Safety profile of Liraglutide: Recent Updates Mohammadreza Rostamzadeh,M.D. Pancreatitis: Victoza post-marketing experience: spontaneous reports of pancreatitis For the majority of the cases, there is
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationKidney Disease, Hypertension and Cardiovascular Risk
1 Kidney Disease, Hypertension and Cardiovascular Risk George Bakris, MD, FAHA, FASN Professor of Medicine Director, Hypertensive Diseases Unit The University of Chicago-Pritzker School of Medicine Chicago,
More informationAdvances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier?
Advances in Technology in the Treatment of Diabetes Mellitus 2017 How far have we come-how far are we going? Is there a final frontier? Alan B Schorr DO FAAIM FACE www.sugardoc.com abs@sugardoc.com Disclosures
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationDu gusts is megl che one. Edoardo Mannucci
Du gusts is megl che one Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer Ingelheim, Eli
More informationCGM and Closing The Loop
CGM and Closing The Loop Dualities Research: Helmsely Charitable Trust, ADA, JDRF, NIDDK Consulting: Abbott Diabetes Care, Roche, Intarcia, Valeritas, Adocia, Big Foot Like With Pumps, We ve Come A Long
More informationDiabetes Management: Current High Tech Innovations
Diabetes Management: Current High Tech Innovations How Far We ve Come in the Last 40 Years William V. Tamborlane, MD Department of Pediatrics Yale School of Medicine Disclosures I am a consultant for:
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationPresented by Dr. Bruce Perkins, MD MPH Dr. Michael Riddell, PhD
Type 1 Diabetes and Exercise: Optimizing the Medtronic MiniMed Veo Insulin Pump and Continuous Glucose Monitoring (CGM) for Better Glucose Control 1,2 for Healthcare Professionals Presented by Dr. Bruce
More informationInsulin Pumps and Glucose Sensors in Diabetes Management
Diabetes Update+ 2014 Congress Whistler, British Columbia Friday March 21, 2014ǀ 8:15 8:45 am Insulin Pumps and Glucose Sensors in Diabetes Management Bruce A Perkins MD MPH Division of Endocrinology Associate
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More informationWhy is Earlier and More Aggressive Treatment of T2 Diabetes Better?
Blood glucose (mmol/l) Why is Earlier and More Aggressive Treatment of T2 Diabetes Better? Disclosures Dr Kennedy has provided CME, been on advisory boards or received travel or conference support from:
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationNon-insulin treatment in Type 1 DM Sang Yong Kim
Non-insulin treatment in Type 1 DM Sang Yong Kim Chosun University Hospital Conflict of interest disclosure None Committee of Scientific Affairs Committee of Scientific Affairs Insulin therapy is the mainstay
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationGuest Speaker Evaluations Viewer Call-In Thanks to our Sponsors: Phone: Fax: Public Health Live T 2 B 2
Public Health Live T 2 B 2 Chronic Kidney Disease in Diabetes: Early Identification and Intervention Guest Speaker Joseph Vassalotti, MD, FASN Chief Medical Officer National Kidney Foundation Thanks to
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationNewer Insulins. Boca Raton Regional Hospital 15th Annual Internal Medicine Conference
Newer Insulins Boca Raton Regional Hospital 15th Annual Internal Medicine Conference Luigi F. Meneghini, MD, MBA Professor of Internal Medicine, UT Southwestern Medical Center Executive Director, Global
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationLEADER and EMPA-REG. John Buse, MD, PhD. University of North Carolina School of Medicine Chapel Hill, NC, USA. Duality of Interest Declaration
1 LEADER and EMPA-REG John Buse, MD, PhD University of Nth Carolina School of Medicine Chapel Hill, NC, USA Duality of Interest Declaration I rept the following potential duality/dualities of interest
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationGli endpoint micro-vascolari nei trial di outcome cardiovascolare
Gli endpoint micro-vascolari nei trial di outcome cardiovascolare Giorgio Sesti University Magna Graecia of Catanzaro ITALY Potenziali conflitti di interesse Il Prof Giorgio Sesti dichiara di aver ricevuto
More informationThe Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections
8/5/217 The Diamond Study: Continuous Glucose Monitoring In Patients on Mulitple Daily Insulin Injections Richard M. Bergenstal, MD Executive Director International Diabetes Center at Park Nicollet Minneapolis,
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationManaging patients with renal disease
Managing patients with renal disease Hiddo Lambers Heerspink, MD University Medical Centre Groningen, The Netherlands Asian Cardio Diabetes Forum April 23 24, 216 Kuala Lumpur, Malaysia Prevalent cases,
More informationMANAGEMENT OF DIABETIC PATIENTS WITH CKD. Roberto Pecoits-Filho, MD, PhD, FASN, FACP PUCPR, Curitiba, BRAZIL
MANAGEMENT OF DIABETIC PATIENTS WITH CKD Roberto Pecoits-Filho, MD, PhD, FASN, FACP PUCPR, Curitiba, BRAZIL Disclosure of Interests Honoraria Astra Zeneca, Novartis Trial participation and research grants
More informationMore Than 1 Year of Hybrid Closed Loop in Pediatrics. Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center
More Than 1 Year of Hybrid Closed Loop in Pediatrics Gregory P. Forlenza, MD Assistant Professor Barbara Davis Center Disclosure Dr. Forlenza has served as a consultant for Abbott Diabetes Care and conducts
More informationCedars Sinai Diabetes. Michael A. Weber
Cedars Sinai Diabetes Michael A. Weber Speaker Disclosures I disclose that I am a Consultant for: Ablative Solutions, Boston Scientific, Boehringer Ingelheim, Eli Lilly, Forest, Medtronics, Novartis, ReCor
More informationADVANCE post trial ObservatioNal Study
Hot Topics in Diabetes 50 th EASD, Vienna 2014 ADVANCE post trial ObservatioNal Study Sophia Zoungas The George Institute The University of Sydney Rationale and Study Design Sophia Zoungas The George Institute
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationINSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION
INSULIN INITIATION AND INTENSIFICATION WITH A FOCUS ON HYPOGLYCEMIA REDUCTION Jaiwant Rangi, MD, FACE Nov 10 th 2018 DISCLOSURES Speaker Novo Nordisk Sanofi-Aventis Boheringer Ingleheim Merck Abbvie Abbott
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationPREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS)
PREVENTION OF NOCTURNAL HYPOGLYCEMIA USING PREDICTIVE LOW GLUCOSE SUSPEND (PLGS) Pathways for Future Treatment and Management of Diabetes H. Peter Chase, MD Carousel of Hope Symposium Beverly Hilton, Beverly
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationACCORD, ADVANCE & VADT. Now what do I do in my practice?
ACCORD, ADVANCE & VADT Now what do I do in my practice? Richard M. Bergenstal, MD International Diabetes Center Park Nicollet Health Services University of Minnesota Minneapolis, MN richard.bergenstal@parknicollet.com
More informationNCT Number: NCT
Efficacy and safety of insulin glargine 300 U/mL vs insulin degludec 100 U/mL in insulin-naïve adults with type 2 diabetes mellitus: Design and baseline characteristics of the BRIGHT study Alice Cheng
More informationEndocrine Update Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh
Endocrine Update 2016 Mary T. Korytkowski MD Division of Endocrinology University of Pittsburgh Disclosure of Financial Relationships Mary Korytkowski MD Honoraria British Medical Journal Diabetes Research
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationGlucose Control and Prevention of Cardiovascular Disease
Glucose Control and Prevention of Cardiovascular Disease Dr Peter A Senior BMedSci MBBS PhD FRCP(E) Associate Professor, Director Division of Endocrinology, University of Alberta Diabetes Update+, March
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationADA Analyst Presentation Saturday 9 th June
ADA Analyst Presentation Saturday 9 th June Carlo Russo Senior Vice-President & Albiglutide Team Leader, GSK Property of GlaxoSmithKline Agenda Welcome & introduction to the Harmony Clinical Programme
More informationGli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1?
Impatto degli inibitori di SGLT-2 nei pazienti con diabete di tipo 2 Corso SID Hotel Michelangelo, Milano. 26 Giugno 2018 Gli inibitori di SGLT-2 possono essere impiegati nel diabete di tipo 1? Emanuele
More information1. Albuminuria an early sign of glomerular damage and renal disease. albuminuria
1. Albuminuria an early sign of glomerular damage and renal disease albuminuria Cardio-renal continuum REGRESS Target organ damage Asymptomatic CKD New risk factors Atherosclerosis Target organ damage
More informationNew basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011
New basal insulins Are they any better? Matthew C. Riddle, MD Professor of Medicine Oregon Health & Science University Keystone Colorado 15 July 2011 Presenter Disclosure I have received the following
More informationEffect of SGLT-2 Inhibitors on the Heart. Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic
Effect of SGLT-2 Inhibitors on the Heart Robert Zimmerman MD Vice Chairman Endocrinology Director Diabetes Center Cleveland Clinic Disclosures Speaker - Johnson and Johnson - Merck Research - Merck - Novo
More informationControl of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim
Control of Glycemic Variability for Reducing Hypoglycemia Jae Hyeon Kim Division of Endocrinology and Metabolism, Samsung Medical Center, Sungkyunkwan University School of Medicine Conflict of interest
More informationProfessor Rudy Bilous James Cook University Hospital
Professor Rudy Bilous James Cook University Hospital Rate per 100 patient years Rate per 100 patient years 16 Risk of retinopathy progression 16 Risk of developing microalbuminuria 12 12 8 8 4 0 0 5 6
More informationHYPERTENSION GUIDELINES WHERE ARE WE IN 2014
HYPERTENSION GUIDELINES WHERE ARE WE IN 2014 Donald J. DiPette MD FACP Special Assistant to the Provost for Health Affairs Distinguished Health Sciences Professor University of South Carolina University
More informationNEWS BRIEFING Diabetes and Cardiovascular Disease. Moderated by: Robert Eckel, MD University of Colorado
NEWS BRIEFING Diabetes and Cardiovascular Disease Moderated by: Robert Eckel, MD University of Colorado 1 EMBARGO POLICY All recordings are for personal use only and not for rebroadcast online or in any
More informationWhat is a CGM? (Continuous Glucose Monitor) The Bionic Pancreas Is Coming
The Bionic Pancreas Is Coming Montana Diabetes Professional Conference October 23, 2014 H. Peter Chase, MD Professor of Pediatrics University of Colorado Barbara Davis Center Stanford: Bruce Buckingham,
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationEmpagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus
Diabetes Ther (2017) 8:33 53 DOI 10.1007/s13300-016-0211-x REVIEW Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus John E. Anderson. Eugene E. Wright Jr.. Charles F.
More informationSupplementary Data. Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles Z T 1 T
Supplementary Data Formula S1. Calculation of IG fluctuation from continuous glucose monitoring profiles 1 T Z T O jig(t) IGjdt IG, interstitial glucose; IG(t), IG value at time t; IG, mean IG from the
More informationBedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L
Diabetes Ther (2018) 9:2155 2162 https://doi.org/10.1007/s13300-018-0507-0 BRIEF REPORT Bedtime-to-Morning Glucose Difference and iglarlixi in Type 2 Diabetes: Post Hoc Analysis of LixiLan-L Ariel Zisman.
More informationSanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes
PRESS RELEASE Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes Dublin, Ireland (15 June 2012) Sanofi presented results
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationCAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION
CAROLINAS CHAPTER/AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS 2016 Annual Meeting HILTON HEAD ISLAND FRIDAY PRESENTATION September 9-11, 2016 ~ Sonesta Resort ~ Hilton Head Island, SC This continuing
More informationTreating Hypertension in Individuals with Diabetes
Treating Hypertension in Individuals with Diabetes Copyright 2017 by Sea Courses Inc. All rights reserved. No part of this document may be reproduced, copied, stored, or transmitted in any form or by any
More informationA factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes
A factorial randomized trial of blood pressure lowering and intensive glucose control in 11,140 patients with type 2 diabetes Hypotheses: Among individuals with type 2 diabetes, the risks of major microvascular
More informationComparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM
Comparing the use of SMBG vs. CGM data to Optimize Glucose Control in T2DM For the first time using CGM to assess glucose control achieved in both groups Richard M. Bergenstal, MD International Diabetes
More informationHot Topics in Diabetic Kidney Disease a primary care perspective
Hot Topics in Diabetic Kidney Disease a primary care perspective DR SARAH DAVIES GP PARTNER WITH SPECIAL INTEREST IN DIABETES, CARDIFF DUK CLINICAL CHAMPION NB MEDICAL HOT TOPICS PRESENTER AND DIABETES
More informationMicrovascular Disease in Type 1 Diabetes
Microvascular Disease in Type 1 Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine The Course
More informationUpdate on CVD and Microvascular Complications in T2D
Update on CVD and Microvascular Complications in T2D Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationinsulin degludec (Tresiba ) is not recommended for use within NHS Scotland.
insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 08 March 2013 The Scottish
More informationSupplementary Online Content
Supplementary Online Content Lingvay I, Manghi FP, García-Hernández P, et al. Effect of insulin glargine up-titration vs insulin degludec/liraglutide on glycated hemoglobin levels in patients with type
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine regardless of the hypoglycaemia definition
More informationDisclosures. Diabetes and Cardiovascular Risk Management. Learning Objectives. Atherosclerotic Cardiovascular Disease
Disclosures Diabetes and Cardiovascular Risk Management Tony Hampton, MD, MBA Medical Director Advocate Aurora Operating System Advocate Aurora Healthcare Downers Grove, IL No conflicts or disclosures
More informationRe-Submission: Published 10 March February 2014
Re-Submission: insulin degludec (Tresiba ) 100units/mL solution for injection in pre-filled pen or cartridge and 200units/mL solution for injection in pre-filled pen SMC No. (856/13) Novo Nordisk 07 February
More informationTRANSPARENCY COMMITTEE
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 17 December 2014 JARDIANCE 10 mg, film-coated tablet B/30 tablets (CIP: 34009 278 928 5 1) JARDIANCE 25 mg, film-coated
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationNo Increased Cardiovascular Risk for Lixisenatide in ELIXA
ON ISSUES IN THE MANAGEMENT OF TYPE 2 DIABETES JUNE 2015 Coverage of data from ADA 2015, June 5 9 in Boston, Massachusetts No Increased Cardiovascular Risk for Lixisenatide in ELIXA First Cardiovascular
More informationThe Role Of SGLT-2 Inhibitors In Clinical Practice. Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs
The Role Of SGLT-2 Inhibitors In Clinical Practice Anne Peters, MD Professor, USC Keck School of Medicine Director, USC Clinical Diabetes Programs Disclosure of Potential Conflicts of Interest Consultantship
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationrazionale della combinazione insulina/glp-1 RAs
Insulina e GLP-1 RAS: insieme o separati? razionale della combinazione insulina/glp-1 RAs Catania Mercure Catania Excelsior 10 ottobre 2017 Andrea Giaccari andrea.giaccari@unicatt.it Centro per le Malattie
More information